COVID-19 in ocrelizumab-treated people with multiple sclerosis-Reference-Cited by-同舟云学术

COVID-19 in ocrelizumab-treated people with multiple sclerosis

Published:2021-04 Issue: Volume:49 Page:102725
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Hughes Richard^ORCID,Whitley Louise^ORCID,Fitovski Kocho,Schneble Hans-Martin^ORCID,Muros Erwan^ORCID,Sauter Annette,Craveiro Licinio,Dillon Paul,Bonati Ulrike^ORCID,Jessop Nikki^ORCID,Pedotti Rosetta,Koendgen Harold

Funder

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference73 articles.

1. SARS-CoV-2 and multiple sclerosis: not all immune-depleting DMTs are equal or bad;Amor;Ann Neurol;,2020

2. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases;Baker;Clin Exp Immunol;,2020

3. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic;Baker;Mult Scler Relat Disord;,2020

4. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study;Bar-Or;Neurology;,2020

5. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic;Brownlee;Neurology;,2020

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Neurological Implications of COVID-19: A Comprehensive Narrative Review;Cureus;2024-05-15

2. Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic;BMJ Neurology Open;2024-04

3. Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic;Acta Neurologica Belgica;2023-11-14

4. Real world study of ocrelizumab in multiple sclerosis: Kuwait experience;Multiple Sclerosis and Related Disorders;2023-11

5. T cell control of SARS-CoV-2: When, which, and where?;Seminars in Immunology;2023-11